Trial Profile
Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel
- Indications Adenocarcinoma; Breast cancer; HER2 positive breast cancer; Inflammatory breast cancer
- Focus Therapeutic Use
- 13 Mar 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 14 Dec 2022 Results (n=45) assessing safety and efficacy of nab-paclitaxel, trastuzumab, and pertuzumab as neoadjuvant therapy, published in the Cancer
- 17 Mar 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.